Background
Inflammatory bowel disease (IBD) is an incurable disease, for which patients need lifelong medication. Current clinical drug delivery methods often cause side effects. Therefore, it is urgent to find a safer and more effective oral colon-targeted delivery platform to alleviate IBD. In contrast to conventional drugs, natural β-glucan has great potential as a functional ingredients-loaded platform to synergistically inhibit IBD, due to its in vivo safety, targeting ability, immunomodulatory, and prebiotic activities.
Scope and approach
The use of β-glucan as a modifiable platform to build a more intelligent delivery system was explored to meet the needs of precise intervention of IBD. We introduced β-glucan as a multi-module delivery platform alone and emphasized its superior properties of integrating with other function modules for co-delivery. Recent advances in the design strategies, structural modifications, and combinatory applications of β-glucan-based carriers were reviewed for oral colon-targeted delivery. Particular attention was paid to the potential of β-glucan to respond to intestinal physiological signals, enabling on-demand release of payloads in inflamed regions.
Key findings and conclusions
The advantages of β-glucan as oral multi-module delivery platforms for precision-targeted management of IBD arise from the modifiable shape/structure, flexible spatial conformation, intestinal immunomodulation, controlled payloads of multiple therapeutics, as well as the ability to regulate intestinal flora and promote intestinal minerals/vitamins absorption. Admittedly, further research is required to overcome the challenges of low yield of natural β-glucan, standardize its toxicology as a carrier, and further clarify the intricate mechanisms underlying the intervention of β-glucan-based delivery platforms in IBD.
扫码关注我们
求助内容:
应助结果提醒方式:
